img

Global and India Infliximab Biosimilar Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and India Infliximab Biosimilar Market Report & Forecast 2024-2034

Market Analysis and InsightsGlobal and India Infliximab Biosimilar Market
This report focuses on global and India Infliximab Biosimilar market, also covers the segmentation data of other regions in regional level and county level.
The global Infliximab Biosimilar revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In India the Infliximab Biosimilar revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Infliximab Biosimilar include Napp Pharmaceuticals Group, Janssen Biotech, Alvogen, Merck, Celltrion, Pfizer(Ac Hospira) and Nippon Kayaku, etc. The global five biggest players hold a share of % in 2024.
Global Infliximab Biosimilar Scope and Market Size
Infliximab Biosimilar market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Infliximab Biosimilar market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For India market, this report focuses on the Infliximab Biosimilar market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in India.



By Company


Napp Pharmaceuticals Group
Janssen Biotech
Alvogen
Merck
Celltrion
Pfizer(Ac Hospira)
Nippon Kayaku
Segment by Type
CT-P13/infliximab-dyyb
Remsima
Inflectra

Segment by Application


Crohn's Disease
Rheumatoid Arthritis
Ulcerative Colitis
Ankylosing Spondylitis
Plaque Psoriasis
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Infliximab Biosimilar definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Infliximab Biosimilar companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Infliximab Biosimilar in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Infliximab Biosimilar sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 Infliximab Biosimilar Product Introduction
1.2 Global Infliximab Biosimilar Outlook 2018 VS 2024 VS 2034
1.2.1 Global Infliximab Biosimilar Sales in US$ Million for the Year 2018-2034
1.2.2 Global Infliximab Biosimilar Sales in Volume for the Year 2018-2034
1.3 India Infliximab Biosimilar Outlook 2018 VS 2024 VS 2034
1.3.1 India Infliximab Biosimilar Sales in US$ Million for the Year 2018-2034
1.3.2 India Infliximab Biosimilar Sales in Volume for the Year 2018-2034
1.4 Infliximab Biosimilar Market Size, India VS Global, 2018 VS 2024 VS 2034
1.4.1 The Market Share of India Infliximab Biosimilar in Global, 2018 VS 2024 VS 2034
1.4.2 The Growth Rate of Infliximab Biosimilar Market Size, India VS Global, 2018 VS 2024 VS 2034
1.5 Infliximab Biosimilar Market Dynamics
1.5.1 Infliximab Biosimilar Industry Trends
1.5.2 Infliximab Biosimilar Market Drivers
1.5.3 Infliximab Biosimilar Market Challenges
1.5.4 Infliximab Biosimilar Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Infliximab Biosimilar by Type
2.1 Infliximab Biosimilar Market Segment by Type
2.1.1 CT-P13/infliximab-dyyb
2.1.2 Remsima
2.1.3 Inflectra
2.2 Global Infliximab Biosimilar Market Size by Type
2.2.1 Global Infliximab Biosimilar Sales in Value, by Type (2018, 2024 & 2034)
2.2.2 Global Infliximab Biosimilar Sales in Volume, by Type (2018, 2024 & 2034)
2.2.3 Global Infliximab Biosimilar Average Selling Price (ASP) by Type (2018, 2024 & 2034)
2.3 India Infliximab Biosimilar Market Size by Type
2.3.1 India Infliximab Biosimilar Sales in Value, by Type (2018, 2024 & 2034)
2.3.2 India Infliximab Biosimilar Sales in Volume, by Type (2018, 2024 & 2034)
2.3.3 India Infliximab Biosimilar Average Selling Price (ASP) by Type (2018, 2024 & 2034)
3 Infliximab Biosimilar by Application
3.1 Infliximab Biosimilar Market Segment by Application
3.1.1 Crohn's Disease
3.1.2 Rheumatoid Arthritis
3.1.3 Ulcerative Colitis
3.1.4 Ankylosing Spondylitis
3.1.5 Plaque Psoriasis
3.1.6 Others
3.2 Global Infliximab Biosimilar Market Size by Application
3.2.1 Global Infliximab Biosimilar Sales in Value, by Application (2018, 2024 & 2034)
3.2.2 Global Infliximab Biosimilar Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 Global Infliximab Biosimilar Average Selling Price (ASP) by Application (2018, 2024 & 2034)
3.3 India Infliximab Biosimilar Market Size by Application
3.3.1 India Infliximab Biosimilar Sales in Value, by Application (2018, 2024 & 2034)
3.3.2 India Infliximab Biosimilar Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 India Infliximab Biosimilar Average Selling Price (ASP) by Application (2018, 2024 & 2034)
4 Global Infliximab Biosimilar Competitor Landscape by Company
4.1 Global Infliximab Biosimilar Market Size by Company
4.1.1 Global Key Manufacturers of Infliximab Biosimilar, Ranked by Revenue (2024)
4.1.2 Global Infliximab Biosimilar Revenue by Manufacturer (2018-2023)
4.1.3 Global Infliximab Biosimilar Sales by Manufacturer (2018-2023)
4.1.4 Global Infliximab Biosimilar Price by Manufacturer (2018-2023)
4.2 Global Infliximab Biosimilar Concentration Ratio (CR)
4.2.1 Infliximab Biosimilar Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Infliximab Biosimilar in 2024
4.2.3 Global Infliximab Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Infliximab Biosimilar, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Infliximab Biosimilar, Product Offered and Application
4.5 Global Key Manufacturers of Infliximab Biosimilar, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 India Infliximab Biosimilar Market Size by Company
4.7.1 Key Players of Infliximab Biosimilar in India, Ranked by Revenue (2024)
4.7.2 India Infliximab Biosimilar Revenue by Players (2018-2023)
4.7.3 India Infliximab Biosimilar Sales by Players (2018-2023)
5 Global Infliximab Biosimilar Market Size by Region
5.1 Global Infliximab Biosimilar Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global Infliximab Biosimilar Market Size in Volume by Region (2018-2034)
5.2.1 Global Infliximab Biosimilar Sales in Volume by Region: 2018-2023
5.2.2 Global Infliximab Biosimilar Sales in Volume Forecast by Region (2024-2034)
5.3 Global Infliximab Biosimilar Market Size in Value by Region (2018-2034)
5.3.1 Global Infliximab Biosimilar Sales in Value by Region: 2018-2023
5.3.2 Global Infliximab Biosimilar Sales in Value by Region: 2024-2034
6 Americas
6.1 Americas Infliximab Biosimilar Market Size YoY Growth 2018-2034
6.2 Americas Infliximab Biosimilar Sales in Volume, by Type (2018, 2024 & 2034)
6.3 Americas Infliximab Biosimilar Sales in Volume, by Application (2018, 2024 & 2034)
6.4 Americas Infliximab Biosimilar Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 Americas Infliximab Biosimilar Sales in Value by Country (2018, 2024 & 2034)
6.4.2 Americas Infliximab Biosimilar Sales in Volume by Country (2018, 2024 & 2034)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Infliximab Biosimilar Market Size YoY Growth 2018-2034
7.2 EMEA Infliximab Biosimilar Sales in Volume, by Type (2018, 2024 & 2034)
7.3 EMEA Infliximab Biosimilar Sales in Volume, by Application (2018, 2024 & 2034)
7.4 EMEA Infliximab Biosimilar Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 EMEA Infliximab Biosimilar Sales in Value by Country (2018, 2024 & 2034)
7.4.2 EMEA Infliximab Biosimilar Sales in Volume by Country (2018, 2024 & 2034)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Infliximab Biosimilar Market Size YoY Growth 2018-2034
8.2 China Infliximab Biosimilar Sales in Volume, by Type (2018, 2024 & 2034)
8.3 China Infliximab Biosimilar Sales in Volume, by Application (2018, 2024 & 2034)
9 APAC
9.1 APAC Infliximab Biosimilar Market Size YoY Growth 2018-2034
9.2 APAC Infliximab Biosimilar Sales in Volume, by Type (2018, 2024 & 2034)
9.3 APAC Infliximab Biosimilar Sales in Volume, by Application (2018, 2024 & 2034)
9.4 APAC Infliximab Biosimilar Market Facts & Figures by Region (2018, 2024 & 2034)
9.4.1 APAC Infliximab Biosimilar Sales in Value by Region (2018, 2024 & 2034)
9.4.2 APAC Infliximab Biosimilar Sales in Volume by Region (2018, 2024 & 2034)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 Napp Pharmaceuticals Group
10.1.1 Napp Pharmaceuticals Group Company Information
10.1.2 Napp Pharmaceuticals Group Description and Business Overview
10.1.3 Napp Pharmaceuticals Group Infliximab Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Napp Pharmaceuticals Group Infliximab Biosimilar Products Offered
10.1.5 Napp Pharmaceuticals Group Recent Development
10.2 Janssen Biotech
10.2.1 Janssen Biotech Company Information
10.2.2 Janssen Biotech Description and Business Overview
10.2.3 Janssen Biotech Infliximab Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Janssen Biotech Infliximab Biosimilar Products Offered
10.2.5 Janssen Biotech Recent Development
10.3 Alvogen
10.3.1 Alvogen Company Information
10.3.2 Alvogen Description and Business Overview
10.3.3 Alvogen Infliximab Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Alvogen Infliximab Biosimilar Products Offered
10.3.5 Alvogen Recent Development
10.4 Merck
10.4.1 Merck Company Information
10.4.2 Merck Description and Business Overview
10.4.3 Merck Infliximab Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Merck Infliximab Biosimilar Products Offered
10.4.5 Merck Recent Development
10.5 Celltrion
10.5.1 Celltrion Company Information
10.5.2 Celltrion Description and Business Overview
10.5.3 Celltrion Infliximab Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Celltrion Infliximab Biosimilar Products Offered
10.5.5 Celltrion Recent Development
10.6 Pfizer(Ac Hospira)
10.6.1 Pfizer(Ac Hospira) Company Information
10.6.2 Pfizer(Ac Hospira) Description and Business Overview
10.6.3 Pfizer(Ac Hospira) Infliximab Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Pfizer(Ac Hospira) Infliximab Biosimilar Products Offered
10.6.5 Pfizer(Ac Hospira) Recent Development
10.7 Nippon Kayaku
10.7.1 Nippon Kayaku Company Information
10.7.2 Nippon Kayaku Description and Business Overview
10.7.3 Nippon Kayaku Infliximab Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Nippon Kayaku Infliximab Biosimilar Products Offered
10.7.5 Nippon Kayaku Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Infliximab Biosimilar Industry Chain Analysis
11.2 Infliximab Biosimilar Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Infliximab Biosimilar Production Mode & Process
11.4 Infliximab Biosimilar Sales and Marketing
11.4.1 Infliximab Biosimilar Sales Channels
11.4.2 Infliximab Biosimilar Distributors
11.5 Infliximab Biosimilar Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. Infliximab Biosimilar CAGR in Value, India VS Global, 2018 VS 2024 VS 2034
Table 2. Infliximab Biosimilar Market Trends
Table 3. Infliximab Biosimilar Market Drivers
Table 4. Infliximab Biosimilar Market Challenges
Table 5. Infliximab Biosimilar Market Restraints
Table 6. Global Infliximab Biosimilar Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. India Infliximab Biosimilar Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Infliximab Biosimilar Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. India Infliximab Biosimilar Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Manufacturers of Infliximab Biosimilar, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global Infliximab Biosimilar Revenue by Manufacturer, (US$ Million), 2018-2023
Table 12. Global Infliximab Biosimilar Revenue Share by Manufacturer, 2018-2023
Table 13. Global Infliximab Biosimilar Sales by Manufacturer, (K Units), 2018-2023
Table 14. Global Infliximab Biosimilar Sales Share by Manufacturer, 2018-2023
Table 15. Global Infliximab Biosimilar Price by Manufacturer (2018-2023) & (US$/Unit)
Table 16. Global Infliximab Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Infliximab Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infliximab Biosimilar as of 2024)
Table 18. Global Key Manufacturers of Infliximab Biosimilar, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of Infliximab Biosimilar, Product Offered and Application
Table 20. Global Key Manufacturers of Infliximab Biosimilar, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of Infliximab Biosimilar in India, Ranked by Revenue (2024) & (US$ million)
Table 23. India Infliximab Biosimilar Revenue by Players, (US$ Million), (2018-2023)
Table 24. India Infliximab Biosimilar Revenue Share by Players, (2018-2023)
Table 25. India Infliximab Biosimilar Sales by Players, (K Units), (2018-2023)
Table 26. India Infliximab Biosimilar Sales Share by Players, (2018-2023)
Table 27. Global Infliximab Biosimilar Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 28. Global Infliximab Biosimilar Sales in Volume by Region (2018-2023) & (K Units)
Table 29. Global Infliximab Biosimilar Sales in Volume Forecast by Region (2024-2034) & (K Units)
Table 30. Global Infliximab Biosimilar Sales in Value by Region (2018-2023) & (US$ Million)
Table 31. Global Infliximab Biosimilar Sales in Value Forecast by Region (2024-2034) & (US$ Million)
Table 32. Americas Infliximab Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. Americas Infliximab Biosimilar Sales in Value by Country (2018-2023) & (US$ Million)
Table 34. Americas Infliximab Biosimilar Sales in Value by Country (2024-2034) & (US$ Million)
Table 35. Americas Infliximab Biosimilar Sales in Volume by Country (2018-2023) & (K Units)
Table 36. Americas Infliximab Biosimilar Sales in Volume by Country (2024-2034) & (K Units)
Table 37. EMEA Infliximab Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. EMEA Infliximab Biosimilar Sales in Value by Country (2018-2023) & (US$ Million)
Table 39. EMEA Infliximab Biosimilar Sales in Value by Country (2024-2034) & (US$ Million)
Table 40. EMEA Infliximab Biosimilar Sales in Volume by Country (2018-2023) & (K Units)
Table 41. EMEA Infliximab Biosimilar Sales in Volume by Country (2024-2034) & (K Units)
Table 42. APAC Infliximab Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. APAC Infliximab Biosimilar Sales in Value by Country (2018-2023) & (US$ Million)
Table 44. APAC Infliximab Biosimilar Sales in Value by Country (2024-2034) & (US$ Million)
Table 45. APAC Infliximab Biosimilar Sales in Volume by Country (2018-2023) & (K Units)
Table 46. APAC Infliximab Biosimilar Sales in Volume by Country (2024-2034) & (K Units)
Table 47. Napp Pharmaceuticals Group Company Information
Table 48. Napp Pharmaceuticals Group Description and Business Overview
Table 49. Napp Pharmaceuticals Group Infliximab Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 50. Napp Pharmaceuticals Group Infliximab Biosimilar Product
Table 51. Napp Pharmaceuticals Group Recent Development
Table 52. Janssen Biotech Company Information
Table 53. Janssen Biotech Description and Business Overview
Table 54. Janssen Biotech Infliximab Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 55. Janssen Biotech Infliximab Biosimilar Product
Table 56. Janssen Biotech Recent Development
Table 57. Alvogen Company Information
Table 58. Alvogen Description and Business Overview
Table 59. Alvogen Infliximab Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 60. Alvogen Infliximab Biosimilar Product
Table 61. Alvogen Recent Development
Table 62. Merck Company Information
Table 63. Merck Description and Business Overview
Table 64. Merck Infliximab Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 65. Merck Infliximab Biosimilar Product
Table 66. Merck Recent Development
Table 67. Celltrion Company Information
Table 68. Celltrion Description and Business Overview
Table 69. Celltrion Infliximab Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 70. Celltrion Infliximab Biosimilar Product
Table 71. Celltrion Recent Development
Table 72. Pfizer(Ac Hospira) Company Information
Table 73. Pfizer(Ac Hospira) Description and Business Overview
Table 74. Pfizer(Ac Hospira) Infliximab Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 75. Pfizer(Ac Hospira) Infliximab Biosimilar Product
Table 76. Pfizer(Ac Hospira) Recent Development
Table 77. Nippon Kayaku Company Information
Table 78. Nippon Kayaku Description and Business Overview
Table 79. Nippon Kayaku Infliximab Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 80. Nippon Kayaku Infliximab Biosimilar Product
Table 81. Nippon Kayaku Recent Development
Table 82. Key Raw Materials Lists
Table 83. Raw Materials Key Suppliers Lists
Table 84. Infliximab Biosimilar Customers List
Table 85. Infliximab Biosimilar Distributors List
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Infliximab Biosimilar Product Picture
Figure 2. Global Infliximab Biosimilar Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global Infliximab Biosimilar Market Size 2018-2034 (US$ Million)
Figure 4. Global Infliximab Biosimilar Sales 2018-2034 (K Units)
Figure 5. India Infliximab Biosimilar Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 6. India Infliximab Biosimilar Market Size 2018-2034 (US$ Million)
Figure 7. India Infliximab Biosimilar Sales 2018-2034 (K Units)
Figure 8. India Infliximab Biosimilar Market Share in Global, in Value (US$ Million) 2018-2034
Figure 9. India Infliximab Biosimilar Market Share in Global, in Volume (K Units) 2018-2034
Figure 10. Infliximab Biosimilar Report Years Considered
Figure 11. Product Picture of CT-P13/infliximab-dyyb
Figure 12. Product Picture of Remsima
Figure 13. Product Picture of Inflectra
Figure 14. Global Infliximab Biosimilar Market Share by Type in 2024 & 2034
Figure 15. Global Infliximab Biosimilar Sales in Value by Type (2018-2034) & (US$ Million)
Figure 16. Global Infliximab Biosimilar Sales Market Share in Value by Type (2018-2034)
Figure 17. Global Infliximab Biosimilar Sales by Type (2018-2034) & (K Units)
Figure 18. Global Infliximab Biosimilar Sales Market Share in Volume by Type (2018-2034)
Figure 19. Global Infliximab Biosimilar Price by Type (2018-2034) & (US$/Unit)
Figure 20. India Infliximab Biosimilar Market Share by Type in 2024 & 2034
Figure 21. India Infliximab Biosimilar Sales in Value by Type (2018-2034) & (US$ Million)
Figure 22. India Infliximab Biosimilar Sales Market Share in Value by Type (2018-2034)
Figure 23. India Infliximab Biosimilar Sales by Type (2018-2034) & (K Units)
Figure 24. India Infliximab Biosimilar Sales Market Share in Volume by Type (2018-2034)
Figure 25. India Infliximab Biosimilar Price by Type (2018-2034) & (US$/Unit)
Figure 26. Product Picture of Crohn's Disease
Figure 27. Product Picture of Rheumatoid Arthritis
Figure 28. Product Picture of Ulcerative Colitis
Figure 29. Product Picture of Ankylosing Spondylitis
Figure 30. Product Picture of Plaque Psoriasis
Figure 31. Product Picture of Others
Figure 32. Global Infliximab Biosimilar Market Share by Application in 2024 & 2034
Figure 33. Global Infliximab Biosimilar Sales in Value by Application (2018-2034) & (US$ Million)
Figure 34. Global Infliximab Biosimilar Sales Market Share in Value by Application (2018-2034)
Figure 35. Global Infliximab Biosimilar Sales by Application (2018-2034) & (K Units)
Figure 36. Global Infliximab Biosimilar Sales Market Share in Volume by Application (2018-2034)
Figure 37. Global Infliximab Biosimilar Price by Application (2018-2034) & (US$/Unit)
Figure 38. India Infliximab Biosimilar Market Share by Application in 2024 & 2034
Figure 39. India Infliximab Biosimilar Sales in Value by Application (2018-2034) & (US$ Million)
Figure 40. India Infliximab Biosimilar Sales Market Share in Value by Application (2018-2034)
Figure 41. India Infliximab Biosimilar Sales by Application (2018-2034) & (K Units)
Figure 42. India Infliximab Biosimilar Sales Market Share in Volume by Application (2018-2034)
Figure 43. India Infliximab Biosimilar Price by Application (2018-2034) & (US$/Unit)
Figure 44. Americas Infliximab Biosimilar Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 45. Americas Infliximab Biosimilar Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 46. Americas Infliximab Biosimilar Sales by Type (2018-2034) & (K Units)
Figure 47. Americas Infliximab Biosimilar Sales Market Share in Volume by Type (2018-2034)
Figure 48. Americas Infliximab Biosimilar Sales by Application (2018-2034) & (K Units)
Figure 49. Americas Infliximab Biosimilar Sales Market Share in Volume by Application (2018-2034)
Figure 50. United States Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 51. Canada Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 52. Mexico Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 53. Brazil Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 54. EMEA Infliximab Biosimilar Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 55. EMEA Infliximab Biosimilar Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 56. EMEA Infliximab Biosimilar Sales by Type (2018-2034) & (K Units)
Figure 57. EMEA Infliximab Biosimilar Sales Market Share in Volume by Type (2018-2034)
Figure 58. EMEA Infliximab Biosimilar Sales by Application (2018-2034) & (K Units)
Figure 59. EMEA Infliximab Biosimilar Sales Market Share in Volume by Application (2018-2034)
Figure 60. Europe Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 61. Middle East Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 62. Africa Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 63. China Infliximab Biosimilar Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 64. China Infliximab Biosimilar Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 65. China Infliximab Biosimilar Sales by Type (2018-2034) & (K Units)
Figure 66. China Infliximab Biosimilar Sales Market Share in Volume by Type (2018-2034)
Figure 67. China Infliximab Biosimilar Sales by Application (2018-2034) & (K Units)
Figure 68. China Infliximab Biosimilar Sales Market Share in Volume by Application (2018-2034)
Figure 69. APAC Infliximab Biosimilar Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 70. APAC Infliximab Biosimilar Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 71. APAC Infliximab Biosimilar Sales by Type (2018-2034) & (K Units)
Figure 72. APAC Infliximab Biosimilar Sales Market Share in Volume by Type (2018-2034)
Figure 73. APAC Infliximab Biosimilar Sales by Application (2018-2034) & (K Units)
Figure 74. APAC Infliximab Biosimilar Sales Market Share in Volume by Application (2018-2034)
Figure 75. Japan Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 76. South Korea Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 77. China Taiwan Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 78. Southeast Asia Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 79. India Infliximab Biosimilar Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 80. Infliximab Biosimilar Value Chain
Figure 81. Infliximab Biosimilar Production Process
Figure 82. Channels of Distribution
Figure 83. Distributors Profiles
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed